Brokers Issue Forecasts for TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at B. Riley issued their Q2 2025 EPS estimates for Tango Therapeutics in a note issued to investors on Monday, June 9th. B. Riley analyst Y. Zhi expects that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.33) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $6.73 million.

Separately, HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.20.

Tango Therapeutics Trading Up 7.5%

TNGX stock opened at $4.47 on Wednesday. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The business’s 50-day moving average is $1.81 and its 200 day moving average is $2.38. The stock has a market cap of $484.52 million, a price-to-earnings ratio of -3.79 and a beta of 1.24.

Institutional Investors Weigh In On Tango Therapeutics

A number of hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas boosted its position in Tango Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after acquiring an additional 3,831 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Tango Therapeutics by 29.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company’s stock worth $65,000 after purchasing an additional 4,813 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Tango Therapeutics by 24.1% during the 4th quarter. Deutsche Bank AG now owns 36,653 shares of the company’s stock worth $113,000 after purchasing an additional 7,128 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Tango Therapeutics by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 22,292 shares of the company’s stock worth $69,000 after purchasing an additional 7,599 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Tango Therapeutics by 9.9% in the first quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company’s stock valued at $155,000 after purchasing an additional 10,213 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.